J&J is showcasing Seltorexant at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Seltorexant is J&J's next potential blockbuster — Phase 3 met all primary/secondary endpoints, outperforming quetiapine XR numerically (57.4% vs 53.4% response). At APA, they'll be teasing the filing timeline and building psychiatrist awareness of the orexin-2 mechanism. MDD + insomnia is an enormous co-morbid population that every psychiatrist manages.
Ask about: NDA filing timeline; how they differentiate from DORAs (Quviviq, Dayvigo) which target both orexin receptors; the MDD3005 26-week data vs. quetiapine XR (the current standard add-on for MDD + insomnia); pricing/access strategy; whether they'll pursue a standalone insomnia indication.
MDD + insomnia requires dual-outcome measurement — VoiceVitals uniquely captures both vocal biomarkers of depression AND sleep quality indicators (vocal fatigue, processing speed correlate with sleep). ePRO+ integrates subjective sleep diaries with objective behavioral assessment.
Position as the outcomes platform that measures what seltorexant uniquely treats — both mood and sleep simultaneously.
Set up a follow-up with J&J's team and Videra Health.
Email Ryan Roberts →